OYOsamu Yamamoto

Osamu Yamamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Osamu Yamamoto has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy

    by Takao Katoh, Hidehiro Kakizaki, Kyu‐Sung Lee, Kota Ishida, Daisuke Katou, Osamu Yamamoto, Jar Jar Jong, Budiwan Sumarsono, Satoshi Uno, Osamu Yamaguchi

    Objectives To investigate the cardiovascular safety of mirabegron add-on treatment to tamsulosin in male patients with residual overactive bladder symptoms. Methods This was a post hoc analysis of MATCH, the first double-blind, placebo-controlled study comparing mirabegron and placebo as add-on therapy to tamsulosin for treatment of overactive bladder in men with lower urinary tract symptoms. The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up. Results Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group). Hypertension (two patients) and increased blood pressure (one patient) were reported in the tamsulosin + placebo group, but there were no blood pressure-related treatment-emergent adverse events among tamsulosin + mirabegron patients. There were no clinically meaningful changes from baseline in blood pressure, and changes in pulse rate were small (+1.2 bpm in the tamsulosin + mirabegron group). Increased pulse rate was more frequent with tamsulosin + mirabegron than with tamsulosin + placebo in older patients, although within the normal range. Conclusions Cardiovascular-related adverse events were uncommon in both treatment groups. Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms.


  • Open Access

    A SURGICAL CASE OF SUPERIOR LUMBAR HERNIA

    by Mamoru Kanazawa, Hiroshi Hiraoka, Kensuke Esato, Osamu Yamamoto, Sinya Koutoku

    The resistance-declined portion in the lumbar region is well known as the lumbar triangle anatomically, and it is extremely rate that hernia occurs in the same region. We experienced a case of superior lumbar hernia presented with a left frank mass. A 70-year-old man was seen at the clinic because of left frank mass which was noticed about one year before. CT revealed a tumor protruded from the defect of the aponeurosis in the lumbar dorsal region. It was inferred that hernia content was the fat around the kidney. With the diagnosis of superior lumbar hernia, herniorrhaphy was performed. Hernia defect, 3cm diamiter and bounded superiorly by the 12th rib, medially by the quadrates lumborum muscle, and laterally by the external oblique, was closed with interrupted nonabsorbable sutures without tension. The postoperative course was uneventful. There has been no recurrence, as of 5 months after the operation.